Ani Pharmaceuticals (ANIP) Operating Expenses (2010 - 2026)

Ani Pharmaceuticals has disclosed Operating Expenses across 17 years of filings, most recently posting $198.6 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $198.6 million, up 16.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $799.9 million (up 19.82% YoY), and the FY2025 annual result was $772.3 million, up 25.82% from the prior year.
• Operating Expenses came in at $198.6 million for Q1 2026 at Ani Pharmaceuticals, down from $212.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $212.3 million in Q4 2025 to a low of $83.7 million in Q1 2022.
• The 5-year median for Operating Expenses is $124.9 million (2023), against an average of $139.8 million.
• Across the five-year window, Operating Expenses surged 62.55% in 2022 and grew 8.9% in 2025, its largest moves.
• Ani Pharmaceuticals' Operating Expenses stood at $92.4 million in 2022, then soared by 35.19% to $124.9 million in 2023, then soared by 56.05% to $195.0 million in 2024, then rose by 8.9% to $212.3 million in 2025, then dropped by 6.46% to $198.6 million in 2026.
• The last three Operating Expenses figures came in at $198.6 million (Q1 2026), $212.3 million (Q4 2025), and $191.6 million (Q3 2025), per Business Quant data.